WebThis is a single center, Phase 1, randomized, open-label, single-dose, 3 treatment, 3-period, 6-sequence, crossover study designed to compare the PK of SMP-100 dissolved in water for oral administration with SMP-100 tablets under fasting conditions, and to evaluate the effect of food on the bioavailability of SMP-100 tablets in healthy subjects. WebMay 14, 2024 · (2024-05-14) SciMount announces FDA approval of SMP-100's IND application for the treatment of Irritable Bowel Syndrome. Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic.
A Phase 1 Study of SMP-100 in Normal Healthy Volunteers
WebMay 14, 2024 · CHENGDU, China I May 13, 2024 I SciMount Pharmatech, Co. Ltd., a wholly-owned subsidiary of Xiling Lab, announces today that the U.S. Food and Drug … WebMar 10, 2024 · Lead Sponsor: Chengdu SciMount Pharmatech Co., Ltd. Source: Chengdu SciMount Pharmatech Co., Ltd. Brief Summary: This will be the first clinical … shands address hospital
Wednesday, February 22, 2024
WebJul 18, 2024 · The company’s pipeline includes innovative treatments for nonalcoholic steatohepatitis (NASH), the orphan disease Prader-Willi syndrome, and irritable bowel syndrome. ConSynance are collaborating with Chengdu SciMount Pharmatech Co., Ltd., a drug discovery company based in China, on the preclinical studies for the IBS project. WebAug 31, 2024 · SMP-100 is a novel serotonin receptor 3 (5-HT3) partial agonist. The compound is under development in an oral dosage form for the treatment of diarrhea … WebTitle: A conformational switch in clathrin light chain regulates lattice structure and endocytosis at the plasma membrane of mammalian cells Author shands alert